CRIS Current Research Information System

FOLLO, MATILDE YUNG
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.093
AS - Asia 7.217
EU - Europa 6.122
AF - Africa 681
SA - Sud America 398
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 17
Totale 22.546
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.986
SG - Singapore 2.221
CN - Cina 1.797
VN - Vietnam 1.644
IT - Italia 1.484
GB - Regno Unito 1.192
DE - Germania 853
SE - Svezia 767
HK - Hong Kong 482
FR - Francia 340
IN - India 325
RU - Federazione Russa 266
BR - Brasile 262
IE - Irlanda 192
NL - Olanda 174
FI - Finlandia 172
JP - Giappone 168
TG - Togo 164
KR - Corea 140
UA - Ucraina 136
SC - Seychelles 133
ZA - Sudafrica 130
CI - Costa d'Avorio 107
NG - Nigeria 99
EE - Estonia 88
HR - Croazia 85
BG - Bulgaria 65
CA - Canada 65
CH - Svizzera 62
AR - Argentina 61
AT - Austria 56
PK - Pakistan 54
ID - Indonesia 48
BE - Belgio 46
BD - Bangladesh 44
JO - Giordania 44
PH - Filippine 43
TH - Thailandia 34
PL - Polonia 30
TR - Turchia 29
MX - Messico 27
ES - Italia 25
TW - Taiwan 23
PT - Portogallo 18
EC - Ecuador 17
GR - Grecia 17
CO - Colombia 16
IQ - Iraq 16
RO - Romania 16
EU - Europa 15
UZ - Uzbekistan 15
IR - Iran 14
AU - Australia 13
VE - Venezuela 13
IL - Israele 12
PY - Paraguay 11
SA - Arabia Saudita 11
LT - Lituania 10
MA - Marocco 10
EG - Egitto 9
MY - Malesia 9
LB - Libano 8
NP - Nepal 7
CL - Cile 6
DZ - Algeria 6
KE - Kenya 5
PE - Perù 5
TN - Tunisia 5
UY - Uruguay 5
AZ - Azerbaigian 4
ET - Etiopia 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
CY - Cipro 3
JM - Giamaica 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LU - Lussemburgo 3
LV - Lettonia 3
NZ - Nuova Zelanda 3
OM - Oman 3
PA - Panama 3
SN - Senegal 3
BO - Bolivia 2
DK - Danimarca 2
GE - Georgia 2
HU - Ungheria 2
MD - Moldavia 2
MK - Macedonia 2
NO - Norvegia 2
RS - Serbia 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BS - Bahamas 1
BW - Botswana 1
Totale 22.524
Salva come PNG Salva come JPEG
Città #
Singapore 1.555
Southend 1.038
Ashburn 894
Fairfield 741
Chandler 657
Bologna 542
Hong Kong 458
Santa Clara 450
Houston 428
Ann Arbor 353
San Jose 336
Woodbridge 335
Wilmington 317
Ho Chi Minh City 311
Seattle 295
Hefei 277
Hanoi 273
Cambridge 256
Princeton 247
Beijing 237
Dublin 192
Boardman 186
Lomé 164
Dong Ket 149
Dallas 137
Helsinki 131
Lauterbourg 121
Tokyo 115
Frankfurt am Main 109
Padova 109
Nanjing 108
Seoul 108
Abidjan 107
Westminster 106
Milan 102
Abeokuta 96
New York 94
Los Angeles 82
Berlin 75
Council Bluffs 72
Buffalo 65
Sofia 65
Shenyang 60
Jinan 58
Jacksonville 56
Munich 55
Saint Petersburg 54
Redondo Beach 53
Changsha 48
Da Nang 48
Redwood City 48
San Diego 47
Turin 47
Bern 46
Florence 45
Medford 45
Brussels 44
Guangzhou 44
Amman 42
Haiphong 41
Vienna 41
Bremen 37
Rome 37
Nanchang 34
Redmond 34
Hebei 33
Shanghai 33
Johannesburg 30
São Paulo 30
Des Moines 29
Tianjin 27
Jakarta 26
Chicago 25
Toronto 25
Amsterdam 24
Bengaluru 24
Hangzhou 24
Nuremberg 23
Dearborn 22
Lappeenranta 22
Udine 22
Warsaw 22
Zhengzhou 22
Rawalpindi 21
London 20
Jiaxing 19
Turku 19
Falkenstein 18
Falls Church 18
Orem 18
Phoenix 18
Atlanta 17
Brooklyn 17
Chennai 17
Hải Dương 17
Montreal 17
Norwalk 17
Yubileyny 17
Bangkok 16
Can Tho 16
Totale 14.322
Salva come PNG Salva come JPEG
Nome #
B-all complexity: Is targeted therapy still a valuable approach for pediatric patients? 302
Clinical and molecular insights in erythropoiesis regulation of signal transduction pathways in myelodysplastic syndromes and β-thalassemia 281
Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes 279
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients 272
A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes 256
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 252
Inositide-Dependent Nuclear Signalling in Health and Disease 245
Cancer therapy and treatments during COVID-19 era 229
Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells. 227
Molecular Characterization of High-Risk MDS Patients Treated with Azacitidine and Lenalidomide: Role of Inositide-Dependent Signalling, Mutations and Microrna 226
Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes 224
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 222
Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q) 221
Clonal activation of Akt in low-risk MDS patients with del(5q) treated with lenalidomide 219
Nuclear Inositides and Inositide-Dependent Signaling Pathways in Myelodysplastic Syndromes 219
Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy 217
AZACITIDINE IN HIGH AND LOW RISK MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF 57 PATIENTS TREATED WITH 4 DIFFERENT THERAPEUTIC REGIMENS 215
Perinatal Stem Cell Spheroids: Insights into Immunomodulation for Type 1 Diabetes Therapy 213
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 213
Specific presence of PKC isoforms in low and fast proliferation Moris hepatoma cells 207
PLC-β1 and cell differentiation: An insight into myogenesis and osteogenesis 207
Nuclear inositide signaling and cell cycle 207
Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients 207
Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells 206
Role of PLCγ1 in the modulation of cell migration and cell invasion in glioblastoma 206
An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes 205
Effect of PKC inhibition on low and fast proliferating Morris rat hepatoma cell line progression 204
Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes 203
Nuclear phospholipase C isoenzyme imbalance leads to pathologies in brain, hematologic, neuromuscular, and fertility disorders 203
Nuclear Inositide Signaling via Phospholipase C 201
Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells. 201
Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients 200
Modulating Phosphoinositide Profiles as a Roadmap for Treatment in Acute Myeloid Leukemia 200
Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS 197
DIFFERENTIAL EFFECT OF LENALIDOMIDE ON INDUCTION OF INOSITIDE-DEPENDENT ERYTHROPOIESIS AND CELL CYCLE IN MYELODYSPLASTIC SYNDROMES 196
Nuclear Localization of Diacylglycerol Kinase Alpha in K562 Cells Is Involved in Cell Cycle Progression 196
Location-dependent role of phospholipase C signaling in the brain: Physiology and pathology 195
Revisiting nuclear phospholipase C signalling in MDS 194
Epigenetic regulation of nuclear inositide signalling in high-risk MDS patients 186
Inositide signaling: Nuclear targets and involvement in myelodysplastic syndromes 184
Inositide signaling in the nucleus: From physiology to pathology. 183
Phosphoinositide-dependent signaling in cancer: A focus on phospholipase C isozymes 183
Frequent Elevation of Akt Kinase Phosphorylation in Blood Marrow and Peripheral Blood Mononuclear Cells from High Risk myelodysplastic Syndrome Patients 182
Multiple forms of PKR present in the nuclei of acute leukemia cells represent an active kinase that is responsive to stress 182
Phospholipase C beta1 (PI-PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS) 182
Subcellular localization relevance and cancer-associated mechanisms of diacylglycerol kinases 181
Real-time PCR as a tool for quantitative analysis of PI-PLCbeta1 gene expression in myelodysplastic syndrome. 178
DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study 177
Phospholipase C-β1 interacts with cyclin E in adipose- derived stem cells osteogenic differentiation 176
Advances in MDS/AML and inositide signalling 174
Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes 173
Nuclear phospholipase C beta1 and cellular differentiation. 172
Physiology and pathology of nuclear phospholipase C beta1 172
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 172
Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression 171
Nuclear PI-PLCβ1 and Myelodysplastic Syndromes: Genetics and Epigenetics 171
Nuclear inositol lipid metabolism: more than just second messenger generation? 170
Signaling pathways and bone marrow microenvironment in myelodysplastic neoplasms 169
Protein kinase C involvement in cell cycle modulation 169
Inositide-dependent phospholipase C signaling mimics insulin in skeletal muscle differentiation by affecting specific regions of the cyclin D3 promoter 165
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation 165
Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy 164
Nuclear Phosphoinositides as Key Determinants of Nuclear Functions 161
Nuclear Nox4-Derived Reactive Oxygen Species in Myelodysplastic Syndromes 161
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 161
PLC and PI3K/Akt/mTOR signalling in disease and cancer 160
CLONAL ACTIVATION OF AKT IN LOW-RISK MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 160
Effect of azacitidine on inositide-dependent signalling pathways in low-risk MDS patients 159
Epigenetic regulation of nuclear PLCbeta1 and Cyclin D3 during Azacitidine treatment 159
Phosphoinositide 3 Kinase signaling in human stem cells from reprogramming to differentiation: A tale in cytoplasmic and nuclear compartments 159
Role of inositide signalling regulation in higher-risk MDS patients during epigenetic therapy 157
PKR Activity Is Required for Acute Leukemic Cell Maintenance and Growth: A Role for PKR-Mediated Phosphatase Activity to Regulate GSK-3 Phosphorylation. 156
Unravelling Heterogeneity of Amplified Human Amniotic Fluid Stem Cells Sub-Populations 156
Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment 155
Modulation of nuclear PI-PLCbeta1 during cell differentiation 155
Glycogen Synthase Kinase-3 and phospholipase C-beta signalling: Roles and possible interactions in myelodysplastic syndromes and acute myeloid leukemia 154
Effects of chloroquine and hydroxychloroquine on the sensitivity of pancreatic cancer cells to targeted therapies 152
Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes 152
Nuclear inositide signaling in myelodysplastic syndromes. 151
The physiology and pathology of inositide signaling in the nucleus 151
Molecular Mechanisms Underlying Psychological Stress and Cancer 150
Nuclear PI-PLCβ1: An appraisal on targets and pathology 149
Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells 149
Nuclear PI-PLCbeta1-Lamin B1 complex signalling during cell cycle progression in human erytholeukemia cells 146
Recent advances in MDS mutation landscape: Splicing and signalling 146
Azacitidine low-dose schedule in low-risk myelodysplastic syndromes. Clinical results of a multicenter phase II study 146
null 144
EFFECT OF LENALIDOMIDE ON INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS 144
Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53 144
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resisten human T-acute leukemia cells by a JNK-dependent mechanism 142
PI-PLCβ1 gene copy number alterations in breast cancer 140
Deciphering signaling pathways in hematopoietic stem cells: the molecular complexity of Myelodysplastic Syndromes (MDS) and leukemic progression 139
Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. 139
PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes 137
Nuclear PI-PLC β1 and Myelodysplastic Syndromes: From Bench to Clinics 137
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. 137
PKC inhibitors induced apoptosis in Morris hepatoma 136
Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals. 136
Nuclear inositide signaling: An appraisal of phospholipase C beta1 behavior in myelodysplastic and leukemia cells 130
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients. 125
Totale 18.203
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.571
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.571
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021731 0 0 0 0 0 0 0 0 0 78 90 563
2021/20222.543 261 37 167 203 226 130 79 147 91 353 418 431
2022/20233.006 282 389 163 401 275 245 162 197 463 61 201 167
2023/20241.097 68 165 98 88 135 164 36 47 68 102 55 71
2024/20253.333 142 429 300 191 608 165 306 123 72 181 149 667
2025/20267.199 625 803 727 510 974 518 921 250 1.417 454 0 0
Totale 23.140